Book signings at #bio2013
Join Michael Salgaller and I as we will be signing our books at the BIO bookstore on Tuesday April 23rd. […]
General Biotechnology
General Biotechnology
The Answers are in the Crowd? (Part 2) [live from #bio2013]
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
The Answers are in the Crowd? (Part 2) [live from #bio2013] Read Post »
General Biotechnology
Which Drug Companies Listed the Most Patents Last Year
This infographic shows the pharmaceutical companies that listed the most patents last year. The companies with the most drug patents
Which Drug Companies Listed the Most Patents Last Year Read Post »
General Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…
Cancer remains the dominant disease target for biotech through to 2010 Read Post »
General Biotechnology, Guest content
After Myriad Oral Argument, Supreme Court Set to Decide Patentability of Isolated Human DNA Molecules
This is a guest post by Morrison & Foerster‘s Marc A. Hearron, James J. Mullen, III and Matthew I. Kreeger. Do you have
General Biotechnology
See you at BIO in Chicago
I will be at BIO 2013, representing BiotechBlog, the Journal of Commercial Biotechnology, and Scientific American Worldview. I look forward
General Biotechnology
The SEC's enforcement programme on biotechnology's communications with the investment community
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The SEC’s enforcement programme on biotechnology’s communications with the investment community
Go to paperABSTRACT: The proliferation of biotechnology star…
General Biotechnology, Guest content
ISO a Scientific Revolution in Cancer Research
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Guest content
Will the UK be the Goose that Lays The Golden Access?
This guest post is from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin
Will the UK be the Goose that Lays The Golden Access? Read Post »
General Biotechnology
Taking stock in biotechnology futures
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Taking stock in biotechnology futures
Go to paperABSTRACT: Investors now have a new tool to help them manage the risk associated with biotechnology investm…